Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Islander, Ulrika ^a   Jochems, Caroline ^a   Stubelius, Alexandra ^a   Andersson, Annica ^a   Lagerquist, Marie K ^a   Ohlsson, Claes ^a   Carlsten, Hans ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Bone mineral density; Collagen induced arthritis; Dexamethasone; Estradiol; Raloxifene

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN; DEXAMETHASONE; RALOXIFENE; ESTRADIOL; ESTROGEN; GLUCOCORTICOID; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE DESTRUCTION; CARTILAGE DEGENERATION; CONTROLLED STUDY; DISEASE MARKER; FEMALE; JOINT DESTRUCTION; MOUSE; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; RHEUMATOID ARTHRITIS; SHAM PROCEDURE; ANIMAL; ARTHRITIS; B LYMPHOCYTE; BONE MARROW; DBA MOUSE; DRUG COMBINATION; DRUG EFFECT; IMMUNOLOGY; JOINT; OSTEOPOROSIS; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; B-LYMPHOCYTES; BONE DENSITY; BONE MARROW; DEXAMETHASONE; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGENS; FEMALE; GLUCOCORTICOIDS; JOINTS; MICE; MICE, INBRED DBA; OSTEOPOROSIS; OVARIECTOMY; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; T-LYMPHOCYTES;

EID: 79959277091     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3371     Document Type: Article

References (51)

1. Kvien TK, Glennas A, Knudsrod OG, Smedstad LM, Mowinckel P, Forre O. The prevalence and severity of rheumatoid arthritis in Oslo. Results from a county register and a population survey. Scand J Rheumatol 1997, 26(6):412-418. 10.3109/03009749709065712, 9433400.
2. Kvien TK, Uhlig T, Odegard S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci 2006, 1069:212-222. 10.1196/annals.1351.019, 16855148.
3. Goemaere S, Ackerman C, Goethals K, De Keyser F, Van der Straeten C, Verbruggen G, Mielants H, Veys EM. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol 1990, 17:1620-1622.
4. Forsblad-D'Elia H, Larsen A, Waltbrand E, Kvist G, Mellstrom D, Saxne T, Ohlsson C, Nordborg E, Carlsten H. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003, 62:617-623. 10.1136/ard.62.7.617, 1754591, 12810422.
5. Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, Frediani B, Cantatore F, Pellerito R, Bartolone S, La Montagna G, Adami S. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 2000, 27:2582-2589.
6. Chantler IW, Davie MW, Evans SF, Rees JS. Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis 2003, 62:350-352. 10.1136/ard.62.4.350, 1754497, 12634236.
7. Lafage-Proust MH, Boudignon B, Thomas T. Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments. Joint Bone Spine 2003, 70:109-118. 10.1016/S1297-319X(03)00016-2, 12713854.
8. Forsblad-D'Elia H, Larsen A, Mattsson LA, Waltbrand E, Kvist G, Mellstrom D, Saxne T, Ohlsson C, Nordborg E, Carlsten H. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003, 30:1456-1463.
9. Stefanick ML. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005, 118(Suppl 12B):64-73.
10. Temin S. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecol Oncol 2009, 115(1):132-134. 10.1016/j.ygyno.2009.06.006, 19716939.
11. Jochems C, Islander U, Kallkopf A, Lagerquist M, Ohlsson C, Carlsten H. Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. Arthritis Rheum 2007, 56(10):3261-3270. 10.1002/art.22873, 17907171.
12. Jochems C, Lagerquist M, Hakansson C, Ohlsson C, Carlsten H. Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin Exp Immunol 2008, 152:593-597. 10.1111/j.1365-2249.2008.03660.x, 2453214, 18435803.
13. Holmdahl R, Bockermann R, Backlund J, Yamada H. The molecular pathogenesis of collagen-induced arthritis in mice--a model for rheumatoid arthritis. Ageing Res Rev 2002, 1:135-147. 10.1016/S0047-6374(01)00371-2, 12039453.
14. Jochems C, Islander U, Erlandsson M, Verdrengh M, Ohlsson C, Carlsten H. Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation. Arthritis Res Ther 2005, 7:R837-843. 10.1186/ar1753, 1175035, 15987485.
15. Holmdahl R, Jansson L, Larsson E, Rubin K, Klareskog L. Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum 1986, 29:106-113. 10.1002/art.1780290114, 3947407.
16. Windahl SH, Vidal O, Andersson G, Gustafsson JA, Ohlsson C. Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J Clin Invest 1999, 104:895-901. 10.1172/JCI6730, 408552, 10510330.
17. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annual Review of Immunology 2000, 18:309-345. 10.1146/annurev.immunol.18.1.309, 10837061.
18. Igarashi H, Medina KL, Yokota T, Rossi MI, Sakaguchi N, Comp PC, Kincade PW. Early lymphoid progenitors in mouse and man are highly sensitive to glucocorticoids. Int Immunol 2005, 17:501-511. 10.1093/intimm/dxh230, 15746243.
19. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007, 28:521-574. 10.1210/er.2007-0001, 17640948.
20. Holmdahl R, Jansson L, Andersson M. Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis Rheum 1986, 29:1501-1509. 10.1002/art.1780291212, 3801072.
21. Yamasaki D, Enokida M, Okano T, Hagino H, Teshima R. Effects of ovariectomy and estrogen replacement therapy on arthritis and bone mineral density in rats with collagen-induced arthritis. Bone 2001, 28:634-640. 10.1016/S8756-3282(01)00426-4, 11425652.
22. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712.
23. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397.
24. Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 2008, 99(2):338-342.
25. Bauer M, Thabault P, Estok D, Christiansen C, Platt R. Low-dose corticosteroids and avascular necrosis of the hip and knee. Pharmacoepidemiol Drug Saf 2000, 9:187-191. 10.1002/1099-1557(200005/06)9:3<187::AID-PDS494>3.0.CO;2-J, 19025819.
26. de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, van Staa TP. Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 2007, 261:170-177.
27. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol 2007, 275:43-61. 10.1016/j.mce.2007.05.015, 17624658.
28. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004, 141:764-770.
29. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994, 37:1499-1505. 10.1002/art.1780371014, 7945476.
30. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992, 7:1063-1069.
31. Carlsten H, Verdrengh M, Taube M. Additive effects of suboptimal doses of estrogen and cortisone on the suppression of T lymphocyte dependent inflammatory responses in mice. Inflamm Res 1996, 45:26-30. 10.1007/BF02263501, 8821775.
32. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2001, 2:65-73. 10.1023/A:1010007108155, 11708295.
33. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274-282. 10.1172/JCI2799, 508885, 9664068.
34. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011, 335:2-13. 10.1016/j.mce.2010.04.005, 3047790, 20398732.
35. Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J Steroid Biochem Mol Biol 2010, 120:69-75. 10.1016/j.jsbmb.2010.03.058, 20346397.
36. Erlandsson MC, Gomori E, Taube M, Carlsten H. Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. Cell Immunol 2000, 205:103-109. 10.1006/cimm.2000.1719, 11104582.
37. Erlandsson MC, Jonsson CA, Lindberg MK, Ohlsson C, Carlsten H. Raloxifene-and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol 2002, 175:319-327. 10.1677/joe.0.1750319, 12429030.
38. Engdahl C, Jochems C, Windahl SH, Borjesson AE, Ohlsson C, Carlsten H, Lagerquist MK. Amelioration of collagen-induced arthritis and immune-associated bone loss through signaling via estrogen receptor alpha, and not estrogen receptor beta or G protein-coupled receptor 30. Arthritis Rheum 2010, 62:524-533.
39. Lindberg MK, Moverare S, Skrtic S, Alatalo S, Halleen J, Mohan S, Gustafsson JA, Ohlsson C. Two different pathways for the maintenance of trabecular bone in adult male mice. J Bone Miner Res 2002, 17:555-562. 10.1359/jbmr.2002.17.4.555, 11918213.
40. Lindberg MK, Weihua Z, Andersson N, Moverare S, Gao H, Vidal O, Erlandsson M, Windahl S, Andersson G, Lubahn DB, Carlsten H, Dahlman-Wright K, Gustafsson JA, Ohlsson C. Estrogen receptor specificity for the effects of estrogen in ovariectomized mice. J Endocrinol 2002, 174:167-178. 10.1677/joe.0.1740167, 12176656.
41. Windahl SH, Andersson N, Chagin AS, Martensson UE, Carlsten H, Olde B, Swanson C, Moverare-Skrtic S, Savendahl L, Lagerquist MK, Leeb-Lundberg LM, Ohlsson C. The role of the G protein-coupled receptor GPR30 in the effects of estrogen in ovariectomized mice. Am J Physiol Endocrinol Metab 2009, 296:E490-496.
42. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999, 281:2189-2197. 10.1001/jama.281.23.2189, 10376571.
43. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282:637-645. 10.1001/jama.282.7.637, 10517716.
44. Li X, Takahashi M, Kushida K, Inoue T. The preventive and interventional effects of raloxifene analog (LY117018 HCL) on osteopenia in ovariectomized rats. J Bone Miner Res 1998, 13:1005-1010. 10.1359/jbmr.1998.13.6.1005, 9626632.
45. Sato M, Kim J, Short LL, Slemenda CW, Bryant HU. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther 1995, 272:1252-1259.
46. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. Faseb J 1996, 10:905-912.
47. Adler RA. Glucocorticoid-induced osteoporosis: management update. Curr Osteoporos Rep 2010, 8:10-14. 10.1007/s11914-010-0003-6, 20425085.
48. Miller PD, Derman RJ. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis?. Osteoporos Int 2010, 21:1793-1802. 10.1007/s00198-010-1208-3, 20309524.
49. Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010, 362:686-696. 10.1056/NEJMoa0808692, 20181970.
50. Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008, 23:525-535.
51. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, Chines AA. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008, 23:1923-1934. 10.1359/jbmr.080710, 18665787.